Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma

Published:2019-12 Issue:6 Volume:29 Page:643-647
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Swami Umang,Monga Varun,Freesmeier Michele,Zhang Weizhou,Bossler Aaron D.,Zakharia Yousef,Milhem Mohammed

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference15 articles.

1. Melanoma.;Schadendorf;Lancet,2018

2. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006);Schachter;Lancet,2017

3. Resistance to PD1/PDL1 checkpoint inhibition.;O’Donnell;Cancer Treat Rev,2017

4. Primary, adaptive, and acquired resistance to cancer immunotherapy.;Sharma;Cell,2017

5. The role of regulatory T cells in cancer immunology.;Whiteside;Immunotargets Ther,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of temozolomide on tumor mutation burden and microsatellite instability in melanoma cells;The Journal of Dermatology;2023-09-02

2. Outcomes From Cytotoxic Chemotherapy Following Progression on Immunotherapy in Metastatic Melanoma: An Institutional Case-Series;Frontiers in Oncology;2022-04-28

3. Successful treatment with dacarbazine against a parathyroid hormone‐related protein‐producing melanoma causing hypercalcemia after immune checkpoint inhibitor failure;The Journal of Dermatology;2022-04-27

4. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation;Cellular & Molecular Biology Letters;2022-03-08

5. Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China;Annals of Translational Medicine;2021-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3